Pharmacokinetics(PK) study of meropenem in Epithelial Lining Fluid (ELF), an open-label study

Pharmacokinetics(PK) study of meropenem in Epithelial Lining Fluid (ELF), an open-label study - PK study of meropenem in ELF

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010941

Enrollment

Registered

2013-06-15

Start date

2013-06-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy volunteer

Interventions

Infusing meropenem 1g in an hour. Infusing meropenem 2g in an hour

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Healthy volunteers except exclusion criteria and abnormalities proved by the pre-medical test. With informed consent as volunteers.

Exclusion criteria

Exclusion criteria: 1) History of hypersensitivity caused by lidocaine hydrochloride. 2) History of hypersensitivity caused by carbapenem. 3) In medication. 4) Creatinine clearance <=30mL/min. 5) Smorker. 6) Hepatic or Renal disorder, Anemia proved by the pre-medical test. 7)Any other participants whose condition is inappropriate for the evaluation of this clinical study, judged by the investigator.

Design outcomes

Primary

Measure	Time frame
To evaluate PK in plasma and ELF of meropenem, the ratio ELF:plasma of meropenem	—

Secondary

Measure	Time frame
To evaluate inflammatory cytokines (IL-1, IL-2, IL-6, IL-10, pro-calcitonine, etc) in serum after BMS.	—

Countries

Japan

Contacts

Public ContactYohei Funatsu

Keio University, School of Medicine Department of Medicine, Division of Pulmonary medicine

dodeko81@ybb.ne.jp03-5363-3793

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026